Millendo Therapeutics (NASDAQ:MLND) Issues Earnings Results, Beats Estimates By $0.07 EPS

Share on StockTwits

Millendo Therapeutics (NASDAQ:MLND) released its earnings results on Monday. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.07, Bloomberg Earnings reports.

Shares of MLND opened at $7.50 on Tuesday. The company has a 50-day moving average price of $10.56. Millendo Therapeutics has a one year low of $6.77 and a one year high of $17.34. The company has a market cap of $100.93 million, a P/E ratio of -0.43 and a beta of 2.64. The company has a current ratio of 7.83, a quick ratio of 7.83 and a debt-to-equity ratio of 0.02.

A number of research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Millendo Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 16th. Oppenheimer assumed coverage on shares of Millendo Therapeutics in a research report on Tuesday, July 16th. They issued an “outperform” rating and a $26.00 target price for the company. Wedbush assumed coverage on shares of Millendo Therapeutics in a research report on Thursday, July 18th. They issued an “outperform” rating and a $24.00 target price for the company. Citigroup assumed coverage on shares of Millendo Therapeutics in a research report on Monday, July 15th. They issued an “outperform” rating and a $26.00 target price for the company. Finally, CIBC assumed coverage on shares of Millendo Therapeutics in a research report on Tuesday, July 16th. They issued an “outperform” rating and a $26.00 target price for the company. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $24.38.

Millendo Therapeutics Company Profile

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Featured Article: Bar Chart

Earnings History for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Inogen Inc  Expected to Announce Earnings of $0.23 Per Share
Inogen Inc Expected to Announce Earnings of $0.23 Per Share
AMN Healthcare Services, Inc.  Given Consensus Rating of “Buy” by Brokerages
AMN Healthcare Services, Inc. Given Consensus Rating of “Buy” by Brokerages
$4.09 Billion in Sales Expected for General Mills, Inc.  This Quarter
$4.09 Billion in Sales Expected for General Mills, Inc. This Quarter
Endeavour Silver Corp  Receives $2.75 Consensus Target Price from Brokerages
Endeavour Silver Corp Receives $2.75 Consensus Target Price from Brokerages
Brokerages Set Alamos Gold Inc  Target Price at $6.77
Brokerages Set Alamos Gold Inc Target Price at $6.77
$0.77 Earnings Per Share Expected for General Mills, Inc.  This Quarter
$0.77 Earnings Per Share Expected for General Mills, Inc. This Quarter


© 2006-2019 Ticker Report